|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Carlson RW et al; NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):1-22. Abstract
Doyle JJ et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23(34):8597-605. Abstract
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687-717. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial conducted by the Eastern Cooperative Oncology Group (E2100). Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Owens MA et al. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5(1):63-9. Abstract
Perez EA et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24(19):3032-8. Abstract
Perez EA et al. Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? San Antonio Breast Cancer Symposium 2005;Poster 2038.
Reddy JC et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 2006;7(2):153-7. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-90. No abstract available
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide
followed by docetaxel (AC
T) with doxorubicin and cyclophosphamide
followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and
trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study.
San Antonio Breast Cancer Symposium 2005;Abstract 1.
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
Wedam SB et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24(5):769-77. Abstract
 |
 |
